Tag Archives: pan-Canadian Pricing Alliance

So – finally! – after Health Canada approved Kalydeco in November 2012 for use in Canada by CF patients aged six years and older who have the specific G551D mutation, it now appears this brilliant new medication will soon be … Continue reading →